ArticleJournal of medicinal chemistry2024

Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.

Martin K Himmelbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.